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1. Main Messages
•	 Needle	syringe	programs	should	continue	and	could	be	increased.
•	 Continuation	of	funding	of	non-occupational	post-exposure	prophylaxis	could	be	considered	if	targeted	to	
men	having	sex	with	men	(MSM)	after	receptive	anal	sex,	rather	than	all	potential	exposures.	
•	 Circumcision	of	MSM	is	recommended	but	could	lead	to	large	upfront	costs	if	all	eligible	men	are	
circumcised	and	there	may	be	significant	cultural	and	social	barriers	to	overcome.
•	 Pre-exposure	prophylaxis	taken	intermittently	is	recommended	for	implementation	subject	to	evidence	
from	studies.			
•	 Early	use	of	antiretrovirals	(ARVs)	would	not	be	recommended	at	current	prices	and	uncertainty	exists	
surrounding	their	effect	on	infectiousness.
•	 Anal	cytology	screening	is	cost-ineffective	compared	to	annual	digital	rectal	screening	for	anal	cancers.
 2. Background 
Huge	improvements	in	the	outlook	for	people	living	with	HIV	have	taken	place	since	the	introduction	of	highly	
active	antiretroviral	medications	with	most	people	expected	to	live	a	near-normal	lifespan.	Previous	estimates	
have	suggested	that	HIV	prevention	was	cost-saving	and	treatment	of	HIV,	cost-effective.	But	rising	rates	of	HIV	
infection	have	brought	into	question	the	effectiveness	and	cost-effectiveness	of	current	prevention	programs	
and	new	biomedical	approaches	for	prevention	have	been	studied.	
3. interventions
We	reviewed	the	literature	on	prevention	and	treatment.	An	expert	panel	of	stakeholders	including	community,	
government,	medical,	and	academic	representatives	chose	six	interventions	for	evaluation	from	the	17	
options	presented	on	the	basis	that	that	they	were	on	the	policy	agenda;	represented	a	mix	of	classic	and	new	
prevention	technologies	and	healthcare;	had	data	to	inform	the	modelling;	and	could	be	brought	together	into	
a	doctoral	research	program.	Unless	otherwise	stated,	the	interventions	were	targeted	at	MSM	in	Australia.
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description of interventions
a)	 needle syringe Programs:	sterile	needles	and	syringes	are	provided	through	needle	syringe	programs	(NSP)	at	no	or	low	cost	as	
well	as	advice	on	injection	behaviour,	safe	sex	and	referral	to	other	services.	Injection	drug	users	were	the	target	population.	
b)	 Adult male circumcision: would	be	a	program	to	circumcise	men	having	sex	with	men	(MSM)	to	prevent	HIV	acquisition.	Four	
target	groups	were	compared:	young	MSM;	MSM	aged	35-44	years	(highest	incidence	of	HIV	acquisition);	insertive	MSM;	and	all	
MSM.	
c)	 non-occupational post-exposure prophylaxis:	provision	of	one	month	supply	of	2-3	antiretroviral	medicines	to	MSM	with	a	recent	
potential	high-risk	sexual	exposure	to	HIV.
d)	 Pre-exposure prophylaxis:	two	antiretrovirals	taken	by	HIV	negative	MSM	with	high	sexual	risk	behaviour	as	well	as	prevention	
counselling	and	medical	monitoring.	Pre-exposure	prophylaxis	could	be	taken	continuously	or	intermittently.	
e)	 Early use of antiretrovirals for treatment and/or prevention:	initiation	of	ARVs	in	all	patients	with	HIV	regardless	of	
CD4	T-cell	count.	
f )	 Anal cytology screening for anal intraepithelial neoplasia:	annual	anal	cytology	in	HIV+	MSM	using	liquid	based	cytology	and	
follow-up	of	high	grade	cytology	by	high	resolution	anoscopy	with	biopsy	and	treatment	of	lesions	with	topical	therapies.	We	also	
considered	a	program	of	annual	digital	rectal	examination	(DRE)	to	detect	early	anal	cancers.	
4. coMparator
The	status-quo	was	the	comparator	for	all	interventions	except	the	NSP	where	a	hypothetical	situation	where	no	program	was	in	place	
applied.
5. results
Needle-syringe	programs	were	cost	saving	at	current	levels	(Table	1)	and	there	would	be	increased	healthcare	cost-savings	if	the	funding	
and	provision	of	sterile	injection	equipment	were	increased	by	50-75%	compared	to	current	levels	of	funding.	Decreased	funding	would	
be	associated	with	greater	decreases	in	health	care	cost-offsets	than	would	be	saved	in	program	costs.	
Adult	male	circumcision	would	be	cost-saving	if	targeted	to	men	who	predominantly	are	the	insertive	partner	in	anal	sex;	it	is	likely	to	
be	cost-effective	if	implemented	for	all	men	but	there	would	be	high	program	costs,	especially	initially;	programs	for	young	men	would	
have	a	significant	likelihood	of	not	being	cost-effective.	
Pre-exposure	prophylaxis	could	have	a	big	impact	on	incidence	and	prevalence	of	HIV	in	men	having	sex	with	men	but	at	high	budget	
costs	at	current	antiretroviral	prices	and	uncertain	cost-effectiveness.	
Post-exposure	prophylaxis,	as	currently	provided	in	Australia,	is	not	cost-effective,	with	a	very	limited	impact	on	HIV	incidence.	If	
targeted	to	HIV	negative	men	having	unprotected	receptive	anal	sex	only,	the	incremental	cost-effectiveness	ratio	is	below	$50,000/
DALY.	
Early	use	of	antiretrovirals	as	treatment	alone	would	not	be	cost-effective	but	the	inclusion	of	the	benefits	of	prevention	would	have	an	
impact	on	the	incremental	cost-effectiveness	ratio,	mainly	by	additional	healthcare	cost-offsets	related	to	fewer	HIV	infections.	
Anal	cytology	screening	may	be	cost-effective	compared	to	no	program	but	has	very	significant	uncertainty	surrounding	the	
incremental	cost-effectiveness	ratio.	However	digital	rectal	examination	is	cost-saving	and/or	cost-effective	compared	to	no	program.	
Table	1:	Health	impact,	costs	and	incremental	cost-effectiveness	ratios	for	six	HIV	interventions	
In	addition	to	the	technical	economic	evaluation	(cost-effectiveness	analysis)	the	steering	committee	discussed	and	evaluated	other	
considerations	that	effect	implementation	of	options	for	change.	These	are	presented	in	Tables	2	and	3	demonstrating	the	reasons	
often	provided	for	changes	to	decisions	when	setting	priorities	in	health.	Acceptability	to	stakeholders	is	often	paramount	in	these	
discussions.
Table	2:	The	stakeholders	ranked	the	interventions	after	the	economic	analyses.	
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Table 1: Health impact, costs and incremental cost-effectiveness ratios for six HIV interventions  
Interventions  
Health impact  
(95% CI or interquartile 
range-IQR) 
Annual 
budget  ICER 
ICER  
(95% CI)   
Needle Syringe 
Programs 
75,000 HIV infections (IQR 
41,000-84,000)  
190,000 HCV infections 
(IQR 185,000-206,000)  
prevented  
365,703 DALYs 
$24m  
Cost-saving  $2.3bn  
(IQR $1.7-$4.0bn)  
Circumcision 
240 to 650 HIV infections 
prevented 
1.4%-3.7% of expected 
incidence 
1,800 to 4,900 DALYs 
Initial $5m to 
$140m 
Ongoing $3m 
to $5m 
  
Circumcision 
insertive 
cost-saving  cost-saving 
Circumcision 
 All MSM 
$8,900/DALY cost-saving to 
$45,000 
Circumcision 
 35-44 year olds 
$9,100/DALY cost-saving to 
$22,000 
Circumcision 
Young 
 $35,000/DALY $700 to 
$110,000 
Pre-exposure 
prophylaxis 
HIV prevalence could fall to 
6.8% over 20 years vs rise 
to 14% with no program.  
95,000 DALYs (55,000 to 
160,000) 
    
Pre-exposure 
prophylaxis 
Continuous 
$420m $46,000/DALY $24,000 to 
$69,000 
Pre-exposure 
prophylaxis 
Intermittent 
$210m $5,600/DALY 
cost-saving to 
$18,000 
Post-exposure 
prophylaxis 
3 HIV infections prevented  
per year 
540 DALYs (430 to 660) 
$3m-$5m $190,000/DALY  
$170,000  to 
$210,000 
Early Rx alone 11,000 DALYs (3,600 to 
20,000)  
$40m  $140,000/DALY $65,000 to 
$350,000 
Early Rx with 
prevention effect 
12,000 DALYs (5400-
14,000) including Rx and 
prevention  
$40m  $59,000/DALY 
cost-saving to 
$143,000 
Anal cytology 2000 (0 to 14,000 )  
DRE 
$450,000  DRE cost-saving 
Cost-saving to 
$37,000 
Cytology $5m 
Cytology 
$33,000/DALY vs nil 
cost-saving to 
$330,000 
Cytology $5m $53,000/DALY vs DRE 
cost-saving to 
$700,000 
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Table 2: The stakeholders ranked the interventions after the economic analyses.  
Decision  Intervention  Main reason  
Should fund 
Needle Syringe Programs 
Pre-exposure prophylaxis 
Cost-saving 
Impact on epidemic 
Could fund 
Circumcision  
Early use of treatment as 
prevention 
Potentially cost-saving 
May be cost-effective if prevention 
effect within plausible limits  
Don’t fund 
Early use of treatment 
Non-occupational post-exposure 
prophylaxis 
Anal cytology 
Not likely to be cost-effective 
Not good value for money 
Lack of evidence  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACE–PrEvEntion PAmPhlEts
Table	3:	Stakeholder	ranking	following	second	stage	filter	discussion
6. aBout ace-prevention
To	aid	priority	setting	in	prevention,	the	Assessing	Cost-Effectiveness	in	Prevention	Project	(ACE-Prevention)	applies	
standardised	evaluation	methods	to	assess	the	cost-effectiveness	of	100	to	150	preventive	interventions,	taking	a	health	
sector	perspective.	This	information	is	intended	to	help	decision	makers	move	resources	from	less	efficient	current	
practices	to	more	efficient	preventive	action	resulting	in	greater	health	gain	for	the	same	outlay.
For	more	information	on	this	topic	area,	please	visit	website	www.sph.uq.edu.au/bodce-ace-prevention
Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
General population results 
1.    Adult depression 
2.    Alcohol 
3.    Blood pressure and cholesterol lowering 
4.    Cannabis 
5.    Cervical cancer screening, Sunsmart and PSA screening 
6.    Childhood mental disorders 
7.    Fruit and vegetables 
8.    HIV 
9.    Obesity 
10.  Osteoporosis 
11.   Physical activity 
12.   Pre diabetes screening 
13.   Psychosis 
14.    Renal replacement therapy, screening and  
early treatment of chronic kidney disease
15.   Salt 
16.   Suicide prevention 
17.   Tobacco   
paMpHlets in tHis series 
 
Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 
E.   Indigenous Health Service Delivery 
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Table 3: Stakeholder ranking following second stage filter discussion 
 
Stakeholder decision  Intervention  Summary of second stage filters 
Should fund 
Needle Syringe Programs Generally acceptable now 
Pre-exposure prophylaxis  
Moral imperative to use available 
technology 
Intermittent use may make more 
cost-effective 
Non-occupational  
post-exposure prophylaxis 
Indemnity risks if person denied 
service acquired HIV.  
Could fund 
Early use of treatment and/or as 
prevention Easy to implement  
Doubtful 
Circumcision  Feasibility and acceptability 
Anal cytology Feasibility and acceptability 
 
 
 
 
 
 
 
